Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients
NCT ID: NCT00202540
Last Updated: 2024-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
38 participants
INTERVENTIONAL
2005-06-30
2006-03-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547
A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.
NCT03507790
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
NCT00006187
An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum
NCT02406027
Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease
NCT00857649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
S18986
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acetylcholinesterase inhibitors stopped at least 3 months before selection
Exclusion Criteria
* Parkinson's disease
* Vascular disorder
* Depression
* Epilepsy
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut de Recherches Internationales Servier
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bruno Vellas, MD
Role: STUDY_CHAIR
Hôpital la Grave-Casselardit, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital la Grave-Casselardit
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CL2-18986-009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.